CoV-2 N (329 a.a.)

Product Name CoV-2 N (329 a.a.)

Product Number SARS-044

Synonym(s) Coronavirus 2019 Nucleocapsid (329 a.a.), Recombinant

Introduction A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019.

The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2)  in humans.

While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus.

The E. coli derived recombinant protein contains the Coronavirus 2019 C-terminal region 329 a.a. from the Nucleocapsid protein and fused to GST-6xHis tag at N-terminal and having a M.W. of 63.5 kDa.

Source E. coli

Purification Method PNTA Sepharose-Affinity Purification

Formulation CoV-2 Nucleocapsid protein solution is supplied in 50mM Tris-HCl pH 8, 1M Urea, and 50% Glycerol.

Stability CoV-2 Spike Protein is shipped on ice packs. Upon arrival, Store at -20°C.

Physical Appearance Sterile filtered clear solution.

CoV-2 Nucleocapsid protein is >95% pure as determined SDS-PAGE.

Storage Conditions -20ºC

Delivery Details 7-10 days

Special Note(s) For research use ONLY. Not for use on humans.

Document(s) SDS